Vivos Therapeutics launches restructuring plan targeting $3.6 million in annual savings starting Q4 2026
Bitget2026/09/29 12:45- Vivos Therapeutics launched a restructuring plan targeting USD 3.6 million in annual cost savings, starting in Q4 2026.
- Measures include staff cuts, vendor changes, renegotiated contracts, with additional reductions effective Oct. 1, 2026.
- Management expects the full run-rate impact of the cost cuts to be reflected in the fourth quarter.
- Combined with revenue initiatives, the company targets cash-flow positive results by late 2026 or early 2027.
- Profitability target remains 2027, supported by ongoing replacement of legacy IT and software systems to reduce labor costs.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barrick’s Marquee gold project faces hazy study timing
Japanese and South Korean stock markets open
Marvell Technology (MRVL.US) $115 billion "merger of the century" faces lukewarm reception! Stock has dropped over 40%, experts estimate only a 50% chance of completion
Marvell plans to acquire Lamington for 115 billions USD to strengthen its position in AI, but the probability of completion is only 50%. The two stocks have dropped by nearly 40% and about 35% respectively, with Chinese regulatory approval being the biggest uncertainty.
Crypto prices
More
